Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Receivables (2016 - 2021)

Historic Receivables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 8 years, with Q3 2021 value amounting to $1.5 million.

  • Viridian Therapeutics, Inc.\DE's Receivables rose 249473.68% to $1.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $1.5 million, marking a year-over-year increase of 249473.68%. This contributed to the annual value of $108000.0 for FY2019, which is 35000.0% up from last year.
  • Viridian Therapeutics, Inc.\DE's Receivables amounted to $1.5 million in Q3 2021, which was up 249473.68% from $57000.0 recorded in Q3 2020.
  • Viridian Therapeutics, Inc.\DE's 5-year Receivables high stood at $5.8 million for Q1 2018, and its period low was $4000.0 during Q1 2020.
  • Its 5-year average for Receivables is $1.2 million, with a median of $979000.0 in 2019.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Receivables crashed by 9989.59% in 2019 and then skyrocketed by 249473.68% in 2021.
  • Viridian Therapeutics, Inc.\DE's Receivables (Quarter) stood at $2.6 million in 2017, then tumbled by 99.06% to $24000.0 in 2018, then soared by 3979.17% to $979000.0 in 2019, then tumbled by 94.18% to $57000.0 in 2020, then skyrocketed by 2494.74% to $1.5 million in 2021.
  • Its Receivables was $1.5 million in Q3 2021, compared to $57000.0 in Q3 2020 and $248000.0 in Q2 2020.